FDA Approves IVIG to Treat Adults with Dermatomyositis
Aug 17, 2021 · On July 15, the U.S. Food & Drug Administration (FDA) approved a 10% solution of a human intravenous immunoglobulin (IVIG), Octagam 10%, to treat adults with dermatomyositis, a rare chronic systemic autoimmune disease with a characteristic skin rash and progressive proximal muscle weakness. 1,2 This treatment was previously FDA approved to ...
FDA Approves First Proven Treatment for Dermatomyositis
Jul 20, 2021 · Octapharma announced that Octagam 10%, an intravenous immune globulin (IVIG), has been approved by the FDA as a therapy for adults with dermatomyositis. Until recently, those who live with dermatomyositis (DM), have relied on off-label medications to treat this rare autoimmune disease of the muscles. On July 16, however, the Food and Drug ...
Trial of Intravenous Immune Globulin in Dermatomyositis
Oct 5, 2022 · Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. Methods. We conducted a randomized, placebo-controlled trial involving patients with...
Dermatomyositis - Diagnosis & treatment - Mayo Clinic
Oct 4, 2024 · The two most common medications for dermatomyositis are azathioprine (Azasan, Imuran) and methotrexate (Trexall). Mycophenolate mofetil (Cellcept) is another medication used to treat dermatomyositis, particularly if the lungs are involved.
Updates in Dermatomyositis: Newer Treatment Options and
Recent advances in classification system to include skin-predominant subtypes, understanding underlying pathogenic mechanisms and the relationship between clinical phenotypes and myositis-specific autoantibodies have led to development of novel therapeutic options.
A comprehensive review of dermatomyositis treatments - from ...
Intravenous immunoglobulin, a well-established treatment in dermatomyositis, has regained prominence and a large randomized clinical trial has reaffirmed its efficacy, confirming it as an effective therapeutic option in this group of patients.
Intravenous Immune Globulin Therapy in Dermatomyositis | New …
Oct 5, 2022 · Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma...
Recent Advances in Pharmacological Treatments of Adult Dermatomyositis …
Aug 31, 2019 · CDM requires oral glucocorticoids; recent studies have evaluated the benefits of adjunctive therapies including methotrexate and calcineurin inhibitors. New therapies target cell populations or cytokines thought to drive disease pathogenesis. Dermatomyositis is an autoimmune disease that remains challenging to treat.
Past, Present, and Future in Dermatomyositis Therapeutics
Jul 26, 2022 · In this review, we provide a review of current medications commonly used for DM, as well as an update on novel pharmacologic therapies in the pipeline. Areas covered include existing and FDA-approved drugs for DM, along with new and emerging treatment targets.
New Myositis Program Treats Patients With a Complex Condition
February 20, 2023. by Christina Frank. In October 2022, Yale Department of Internal Medicine’s Section of Rheumatology, Allergy & Immunology established a Yale Medicine Myositis Program —an interdisciplinary clinic geared to caring for people with this complex condition that can affect almost every system in the body.